Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

Related Articles by Review for PubMed (Select 16111439)

1.

Reducing patient drug acquisition costs can lower diabetes health claims.

Mahoney JJ.

Am J Manag Care. 2005 Aug;11(5 Suppl):S170-6.

2.
3.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association.

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
4.

Are incentive-based formularies inversely associated with drug utilization in managed care?

Gleason PP, Gunderson BW, Gericke KR.

Ann Pharmacother. 2005 Feb;39(2):339-45. Epub 2005 Jan 11. Review.

PMID:
15644478
5.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

6.

Cost-effective management of type 2 diabetes: providing quality care in a cost-constrained environment.

Steffens B.

Am J Manag Care. 2000 Aug;6(13 Suppl):S697-703; discussion S704-9. Review.

7.

The economics of pharmacotherapy for diabetes mellitus.

Costa B, Arroyo J, Sabaté A.

Pharmacoeconomics. 1997 Feb;11(2):139-58. Review.

PMID:
10165825
8.

Controlling costs and improving diabetes care.

Eichner HL.

Case Manager. 2002 Mar-Apr;13(2):75-7. Review.

PMID:
11901374
9.
10.

Six strategies to identify and assist patients burdened by out-of-pocket prescription costs.

Alexander GC, Tseng CW.

Cleve Clin J Med. 2004 May;71(5):433-7. Review.

PMID:
15195778
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk